Home » Newsletters » BioWorld Science

BioWorld Science

April 18, 2007

View Archived Issues

Snapshots of clinical trials in cardiology

Orally bioavailable anthracycline penetrates the CNS in mice

Novel agents for HIV infection reported in recent Pfizer patent

Ccr2 protective in Alzheimer's disease

Genetic studies allow creation of test for clozapine-induced agranulocytosis risk

Clevudine metabolism studied in human hepatocytes

New therapeutic options for hepatitis C described in recent patent literature

Novel therapeutic agents for neurological disorders reported in recent patents

Cerus presents preclinical data on two new L. monocytogenes-based immunotherapeutics

Further analysis of CRD5 phase I/II data

ACE and NMRC begin Campylobacter challenge study

Syndax licenses selective HDAC inhibitor from Bayer Schering Pharma

Thallion updates progress of FDA Advisory Committee meeting on STEC infection

Galapagos signs new collaborations with Ono

AGI receives FDA approval for phase III study of arverapamil

Bayer and WHO sign agreement for Lampit provision for Chagas disease

MultiCell signs supply agreement with Lundbeck

Pevion and Mymetics sign virosome technology license agreement

TopoTarget to acquire Apoxis

Multikinase inhibitor from Amgen with antiangiogenic and antitumor activity

LY-2401401, a new multikinase inhibitor, presented at the AACR meeting

VEGFR inhibitor with potent antitumor activity alone and in combination

Novel series of substituted pyrroles shows promise for the treatment of breast cancer

Eisai completes Morphotek acquisition

Renvela meets primary endpoint in hyperphosphatemic patients

BNC-105, a vascular disruption agent with an improved therapeutic index

Merck seeks new indications for Gardasil for vaginal and vulvar cancers

Once-weekly formulation of risedronate sodium approved in Japan

Avastin approved in Japan for advanced or recurrent colorectal cancer

Reclast approved for Paget's disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Wuxi Apptec insists it’s ‘not a Chinese military company’
BioWorld
Wuxi Apptec isn’t going down without a fight after the U.S. Department of Defense added it to the Section 1260H list June 8 as a designated “Chinese military...
Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors
BioWorld Science
Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.